Introduction {#s0005}
============

Primary central nervous system lymphoma (PCNSL) accounts for approximately 5% of all newly diagnosed brain tumors, predominantly affecting older patients [@bb0005]. It is a non-Hodgkin-lymphoma (NHL), strictly limited to the central nervous system (CNS), occurring in immuno-competent and immuno-compromised patients [@bb0010]. In approximately 90% of all manifestations, PCNSL are diffuse large B-cell type lymphomas [@bb0015]. Compared to other high-grade NHL outside the CNS, PCNSL is particularly aggressive and overall survival is poor. So far, management of PCNSL remains controversial and independent from the individual therapeutic approaches, disease recurrence is almost certain in the vast majority of patients [@bb0020]. The high recurrence rate of PCNSL is believed to reflect the peculiarity of the immune-privilege of the CNS, providing a niche for the tumor cells, eventually resulting in minimal residual disease as a starting point for relapse [@bb0025].

Although PNCSL represents a rather rare CNS malignancy, a number of controlled trials have investigated promising cyto-reductive treatment regimens [@bb0030]. During recent years, whole brain radiation has been applied less frequently, since it bears almost no curative potential, although initial response to therapy is striking [@bb0035]. Multidrug-chemotherapy approaches, mostly based on methotrexate, are increasingly performed with beneficial outcomes. Results of complementary, non-methotrexate based chemotherapeutic approaches, for example in combination with autologous stem cell transplantation, might represent an effective alternative possibly associated with superior outcomes [@bb0025].

However, reliable, continuous non-invasive monitoring of response to anti-proliferative medication is becoming increasingly important for the oncologist to assess and compare efficacy of PCNSL treatments [@bb0040]. Cross sectional imaging, most importantly magnetic resonance imaging (MRI), has been shown to be of excellent accuracy regarding the diagnosis of intracranial lymphoma [@bb0045] and therefore is a propitious technique for this purpose. Although conventional MRI, including T2 weighted imaging, T1 weighted imaging, fluid attenuated inversion recovery (FLAIR) -- imaging and gadolinium-enhanced imaging provides detailed information on localization, mass effect, blood brain barrier disruption, peri-focal edema and extent of infiltration of CNS mass lesions, it (very sensitively) visualizes only unspecific phenomena [@bb0050] and does not sufficiently reflect histopathological features of brain tumors [@bb0055].

Contrarily to conventional MRI, diffusion weighted imaging (DWI), a technique employing opposing gradients to visualize the motion of hydrogen nuclei on a microscopical scale, provides apparent diffusion coefficient (ADC) maps, which reflect microstructural features of biological tissues, and hence, can be employed as an imaging biomarker in various neoplastic conditions [@bb0060], [@bb0065]. As an example, ADC values derived from small singular region of interest (ROI) measurements in pre-operative ADC maps of PCNSL patients, accurately representing the stereotactically biopsied specimen, precisely predicted the proliferative activity of the respective PCNSL manifestation [@bb0070].

However, the singular ROI method in the diagnostic pre-operative or follow-up setting has significant limitations, for example -- inherent to the method -- it cannot reflect features of the whole continuum of the space occupying lesion, and hence, tumor heterogeneity is not sufficiently depicted. Furthermore, inter-rater variability is another significant concern [@bb0075].

As a consequence, the aim of this study was to evaluate whether whole tumor histogram-profiling in preoperative ADC maps of PCNSL patients sufficiently reflects corresponding (immune-) histopathological properties like Ki-67 expression, cellular density and nuclear area, perspectively providing a sensitive tool for monitoring therapy-related changes of the tumor-architecture on a microscopical level.

Patients, Procedures and Methods {#s0010}
================================

Patients Collective {#s0015}
-------------------

Our radiological information system was searched for the diagnosis PCNSL. Twenty-one patients were finally included, all of which had confirmation by stereotactic biopsy and subsequent neuropathological workup in our hospital. The patients' collective was comprised of 8 female and 13 male subjects; ranging from 28 to 89 years with a mean age of 67.7 years. Informed consent was obtained in writing from all patients or caregivers for the asservation of sample remnants and compiling of clinical and radiological data. The study was approved by the local ethics committee (Ethikkommission Universität Leipzig, Az 330-13-18112013). Requirements for the study were sufficient pretreatment MRI scans including DWI. MRI examinations of the included patients did not reveal signs of hemorrhage or calcifications.

MRI specifics {#s0020}
-------------

All images were acquired in the clinical diagnostic routine using a 1.5Tesla MRI system (Siemens Magnetom Symphony 1,5T) with the standard Siemens head coil (CP head array, model \#1P3146037). DWI was performed using a single shot echo planar sequence with following parameters: Echo time(TE)/Repetition time(TR) = 6000/105 ms, 90° flip angle, 57 transverse sections, slice thickness = 5 mm, field of view (FOV) = 230 mm. Diffusion-sensitizing gradients were applied sequentially in the x, y and z directions with b factors of 0 and 1000 s/mm2. ADC maps were then automatically generated by the operating console of the MR scanner. Postcontrast T1-weighted 3D-gradient echo sequence(GRE) imaging was obtained with following parameters: TR/TE = 2150/3.93 ms, flip angle 15°, 1-mm section thickness and 230 mm FOV. A standard dose (0.1 mmol/kg body weight) of gadolinium based contrast agent (Gadovist, Bayer, Leverkusen, Germany) was injected intravenously. Routine anatomic precontrast T1/T2_tirm_tra_dark_fluid (TR/TE = 9000/114, slice thickness 5mm, flip angle 150°, 28 transverse sections) images were also obtained.

All images were available in digital form and analyzed by one experienced radiologist (SS) without knowledge of the histopathological diagnosis on a PACS workstation (syngo.plaza VB20, Siemens, Germany).

Histogram Profiling of ADC Maps {#s0025}
-------------------------------

ADC maps and T1weighted post contrast images were exported from our radiological archive in DICOM format *via* the aforementioned Siemens PACS. Using a custom-made DICOM image analysis tool (programmed by N.G. using Matlab, The Mathworks, Natick, MA), whole tumor diffusion profile analysis *via* the histogram approach was performed as follows; T1weighted post-Gadolinium images were displayed in a graphical user interface (GUI) to tag the contrast-enhancing tumor of each patient in all respective MRI sections. All drawn regions of interest (ROIs) were then automatically propagated onto the corresponding ADC maps and the whole lesion histogram profile was consecutively calculated, providing the following set of parameters: ADCmean, ADCmin, ADCmax, ADCp10, ADCp25, ADCp75, ADCp90, ADCmodus, ADCmedian, Skewness, Kurtosis, and Entropy.

Neuropathology {#s0030}
--------------

All tumor specimens were used for neuro-histological confirmation of the diagnosis. A 5μm section of each tumor was stained by H&E and a further section was employed for Ki-67 immunohistochemistry to determine the proliferation rate [@bb0070], as previously reported.

The (immune-) histopathological images were digitalized with a Jenalumar microscope, carrying a 4.2 digital camera (Zeiss, Jena, Germany). Thereupon, Ki-67 index, cell count, average nuclear area and total nuclear area of each specimen were quantified using the ImageJ particles tool [@bb0080] as described previously.

Statistical Analysis {#s0035}
--------------------

Statistical analysis including graphics creation was performed using SPSS 23.0 (SPSS Inc, Chicago, IL).

Firstly, DWI histogram profile information and (immune-)histopathological data were investigated using descriptive statistics. Secondly, data was tested for Gaussian distribution using the Shapiro-Wilk Test. Finally, correlation analysis for normally distributed parameters was performed using Pearson Correlation Coefficient. In case of non-Gaussian distribution, Spearman-Rho Rank-Order Correlation was performed. *P* \< .05 was taken to indicate statistical significance in all instances.

Results {#s0040}
=======

Two examples of cranial MRI including the corresponding whole-tumor ADC-histograms and Ki-67 stainings from patient suffering from PCNSL are given in [Figure 1](#f0005){ref-type="fig"}).Figure 1MR-Imaging, Ki-67 staining and ADC histograms of two exemplary PCNSL patients. A-D and E-H show two examples of PCNSL. A and E are giving the T1 post contrast images of both individuals, B and F display the corresponding section of the ADC map. C and F show the respective ADC histograms. D and H represent Ki-67 staining of the biopsy specimen.Figure 1

The results of the descriptive analysis on DWI data and histopathological information are summarized in [Table 1](#t0005){ref-type="table"}). Shapiro-Wilk-Test revealed Gaussian distribution for ADCmean, ADCmin, ADCmax, ADCp10, ADCp25, ADCp75, ADCp90, ADCmodus, ADCmedian, Skewness, Entropy, cell count, total nuclear area and Ki-67 (data not shown). Non-Gaussian distribution was determined for Kurtosis and average nuclear area (data not shown).Table 1DWI Histogram Profiling and Neuropathologic Parameters of All Investigated PCNSLTable 1ParametersMean ± Standard DeviationMinimumMaximumADC~mean~, × 10^-5^ mm^2^s^-1^98.56 ± 16.4973.02137.55ADC~min~, × 10^-5^ mm^2^s^-1^57.45 ± 19.4013.3792.11ADC~max~, × 10^-5^ mm^2^s^-1^190.49 ± 48.2286.54313.53P10 ADC, × 10^-5^ mm^2^s^-1^77.16 ± 13.4954.81106.70P25 ADC, × 10^-5^ mm^2^s^-1^85.34 ± 15.7660.09120.20P75 ADC, × 10^-5^ mm^2^s^-1^109.95 ± 19.8575.33157.38P90 ADC, × 10^-5^ mm^2^s^-1^125.19 ± 21.7576.18172.29Median ADC, × 10^-5^ mm^2^s^-1^95.88 ± 18.1872.40137.29Mode ADC, × 10^-5^ mm^2^s^-1^90.68 ± 22.5055.34140.30Kurtosis4.72 ± 3.052.1714.63Skewness0.85 ± 0.77-0.422.51Entropy4.22 ± 0.692.795.55Cell count, n1288.62 ± 366.693191922Total Nuclear Area, μm106617.71 ± 44549.1319988.01216517.76Average Nuclear Area, μm86.49 ± 46.4153.20267.91Ki-67, %76.19 ± 12.5450.095.0

Pearson's correlation coefficient was used to investigate the association between ADCmean, ADCp10, ADCp25, ADCp75, ADCp90, ADCmodus, ADCmedian, Skewness, Entropy, cell count, total nuclear area and Ki-67. Spearman-Rho Rank-Order Correlation was calculated to investigate the association between Kurtosis, cell count, average nuclear area, total nuclear area and Ki-67. Also, correlations between average nuclear area and all evaluated DWI histogram data were calculated using Spearman-Rho Rank-Order. Significant correlations were identified for the following pairs of parameters; ADCmean and Ki-67 (r = −0.434, p = 0.049), ADCmean and total nuclear area (r = -0.462, p = 0.035), ADCp10 and cell count (r = -0.435, p =0.049), ADCp10 and total nuclear area (r = -0.455, *P* = .038), ADCp25 and total nuclear area (r = -0.458, , *P* = .037) ADCp90 and Ki-67 (r = -0.439, , *P* = .047), Kurtosis and cell count (r = 0.458, , *P* = .037). The results of the correlative analysis are summarized in [Table 2](#t0010){ref-type="table"}). [Figure 2](#f0010){ref-type="fig"}) is showing the identified significant correlations as dot plots.Figure 2Identified correlations between immune-histopathological parameters and whole-tumor ADC-profiling. ADCmean values correlate with Ki-67 expression and average nuclei area. The lower percentiles, p10 and p25 correlate with structural parameters of the histopathological analysis -- cell count and average nuclei area. P90, contrarily, only correlates with Ki-67 expression. The peakedness of the ADC histogram -- kurtosis -- correlates with cell count.Figure 2Table 2Correlations of DWI-Histogram Profile Parameters with Cellular Density, Total Nuclear Area and Average Nuclear Area as Well as Ki-67 in All Investigated PCNSLTable 2DWI Histogram Profile ParametersCell Count (n)Total Nuclear Area (μm^2^)Average Nuclear Area (μm^2^)Ki-67 (%)ADC~mean~, × 10^-5^ mm^2^s^-1^r = -0.390r = -0.462r = - 0.254r = -0.434*P* = .080*P* = .035*P* = .267*P* = .049ADC~min~, × 10^-5^ mm^2^s^-1^r = -0.275r = -0.338r = -0.289r = -0.223p=0.228*P* = .135*P* = .204*P* = .332ADC~max~, × 10^-5^ mm^2^s^-1^r = 0.200r = -0.048r = -0.153r = -0.373*P* = .386*P* = .835*P* = .597*P* = .096ADCp10, × 10^-5^ mm^2^s^-1^r = -0.435r = -0.455r = - 0.234r = -0.409*P* = .049*P* = .038*P* = .308*P* = .066ADCp25, × 10^-5^ mm^2^s^-1^r = -0.400r = -0.458r = -0.255r = - 0.380*P* = .072*P* = .037*P* = .264*P* = .089ADCp75, × 10^-5^ mm^2^s^-1^r = -0.368r = -0.406r = -0.202r = -0.388*P* = .100*P* = .068*P* = .381*P* = .082ADCp90, × 10^-5^ mm^2^s^-1^r = -0.343r = -0.411r = -0.202r = -0.439*P* = .128*P* = .064*P* = .379*P* = .047ADCMedian, × 10^-5^ mm^2^s^-1^r = -0.368r = -0.419r = -0.235r = -0.363*P* = .100*P* = .059*P* = .306*P* = .106ADCModus, × 10^-5^ mm^2^s^-1^r = -0.256r = -0.373r = -0.265r = -0.232*P* = .262*P* = .096*P* = .245*P* = .311Kurtosisr = -0.458r= 0.175r = -0.136r = 0.035*P* = .037*P* = .448*P* = .558*P* = .882Skewnessr = 0.338r = 0.201r = -0.001r = -0.036*P* = .134*P* = .383*P* = .998*P* = .876Entropyr = 0.053r = -0.023r = 0.067r = -0.263*P* = .820*P* = .923*P* = .774*P* = .248

Discussion {#s0045}
==========

In this study we aimed to investigate, whether whole tumor ADC histogram-profiling sufficiently reflects microscopical tumor-architecture and proliferative activity of PCNSL.

To our best knowledge, this work is the first showing statistically significant associations between ADC histogram-profiling parameters and prognostically relevant (immune-)histopathological features in a collective of PCNSL patients.

In detail, kurtosis of the whole tumor ADC histogram correlated with cellular density of the investigated PCNSL, indicating that increased kurtosis reflects high cellularity in this specific malignant neoplastic CNS lesion. This finding conforms with the results of a recently published investigation of malignant tumors in the thyroid gland, showing that cellularity in thyroid carcinoma is associated with kurtosis of the whole tumor ADC histogram [@bb0085]. Our findings are further corroborated by the study of Kyriazi et al. [@bb0090], who were able to demonstrate that changes in ADC histogram kurtosis correlate with response to cyto-reductive chemotherapy in metastatic ovarian and primary peritoneal cancer, as well as with the study of Foroutan et al. [@bb0095], who demonstrated early changes in ADC histogram kurtosis as a sign of response to anti-proliferative treatment in a xenotransplant model of osteosarcoma.

Interestingly, skewness and entropy of the whole tumor ADC histogram were not significantly correlated with (immune-) histopathological features in our investigation. Other malignant entities -- for example cervical carcinomas, however, revealed correlations between entropy and skewness of ADC histograms and histopathological features, which is probably a consequence of the distinct cellular- and matrix-architecture of the respective tumors, which are composed of a stromal and an epithelial compartment, other than the typically very homogeneous PCNSL [@bb0100], [@bb0105].

Additionally, the lower percentiles of whole tumor diffusion profiling (p10 and p25) showed significant correlations with measures of cellularity and chromatin content, features representing tumor viability and progression. This result is underlined by a previous work investigating uterine cervical carcinomas with and without metastatic dissemination [@bb0100]. This study revealed significantly different values in the tenth percentile of whole tumor ADC values when comparing manifestations of the disease, which already had gained the ability to spread metastatically with non-metastasized manifestations. Our findings further coincide with the earlier work of Kyriazi and coworkers, which demonstrated changes in ADC p10 values as an expression of response to chemotherapy in ovarian and peritoneal cancer [@bb0090].

The ninetieth percentile of whole tumor diffusion profiling (p90) showed a statistically significant, inverse correlation with the expression of Ki-67, a nuclear protein being only detectable during active proliferation [@bb0110]. An almost identical correlation was identified in thyroid carcinomas, as published previously [@bb0085]. This, so far, suggests a specific sensitivity of the 90th percentile for the reflection of the proliferative activity of malignant tumors.

In concordance with the results of our previously published study, which used a singular ROI for ADC quantification [@bb0070], mean values of whole tumor diffusion profiling did correlate significantly with Ki-67 expression and total nuclear area, representing surrogate markers for active proliferation and chromatin content in the tumor. The mean value of ADC quantification obtained *via* both, the whole lesion and the singular-one-slice ROI approach, has been demonstrated to very well reflect cellularity and proliferative activity in different malignant conditions [@bb0115], even though singular ROIS are significantly less accurate than the whole lesion approach [@bb0075]. However, the mean value of ADC quantification as a singular parameter cannot sufficiently provide a whole spectrum of information about the complexity of the micro-architecture of a neoplastic tissue, but rather creates a significantly filtered and condensed approximation.

Thus we conclude that whole tumor ADC histogram profiling, giving a comprehensible number of different parameters that relatively specifically reflect different aspects of clinical relevant tumor biology, is a very useful extension of the commonly employed singular ROI technique.

Our study suffers from some limitations. Firstly, it is only a retrospective study and confined to a small quantity of PCNSL patients. Secondly, the study did not include 3T images and therefore is only representative for the lower magnetic field strength. Furthermore, comparability of the obtained values between different 1.5T scanners is still uncertain and must be validated in further investigations.

Conclusions {#s0050}
===========

Whole tumor histogram-profiling of ADC maps provides a comprehensible set of parameters, which are very useful for pre-treatment estimation of tumor biological properties of PCNSL. The technique is a promising candidate for a non-invasively obtained biomarker, probably allowing for sensitive and specific estimation of tumor response to cyto-reductive treatment regimens. However, further prospective studies are warranted to validate our findings.
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